GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » First Wave BioPharma Inc (NAS:FWBI) » Definitions » Cash Flow from Investing

First Wave BioPharma (First Wave BioPharma) Cash Flow from Investing : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is First Wave BioPharma Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, First Wave BioPharma spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, First Wave BioPharma gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


First Wave BioPharma Cash Flow from Investing Historical Data

The historical data trend for First Wave BioPharma's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

First Wave BioPharma Cash Flow from Investing Chart

First Wave BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 0.09 -10.32 - -0.50

First Wave BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

First Wave BioPharma Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

First Wave BioPharma's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

First Wave BioPharma's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


First Wave BioPharma  (NAS:FWBI) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

First Wave BioPharma's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

First Wave BioPharma's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

First Wave BioPharma's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

First Wave BioPharma's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

First Wave BioPharma's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

First Wave BioPharma's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

First Wave BioPharma's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

First Wave BioPharma's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means First Wave BioPharma paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

First Wave BioPharma's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means First Wave BioPharma paid $0.00 Mil for other investing activities.


First Wave BioPharma Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of First Wave BioPharma's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


First Wave BioPharma (First Wave BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Executives
James Sapirstein director, officer: President and CEO 1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano officer: Chief Financial Officer 271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman director 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell director C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm director 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes director 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington officer: CHIEF MEDICAL OFFICER 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman officer: CHIEF FINANCIAL OFFICER 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr. 10 percent owner C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor director, officer: President and CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc 10 percent owner PO BOX 2422, WESTPORT CT 06880